An HHS Official Praised Hormone Changes. Her Startup Ties Drew an Ethics Complaint.

Campaign Legal Center filed a complaint with the HHS inspector general on November 12 asking the office to investigate possible federal ethics violations by Advanced Research Projects Agency for Health Director Alicia Jackson. The filing ties its request to Jackson’s appearance at a November 10, 2025 HHS event announcing changes to FDA hormone-therapy warnings and to her financial-disclosure record.

The complaint is an allegation, not a finding. It says it was submitted through the inspector general’s hotline. HHS-OIG says not every hotline complaint results in an investigation and that it generally will not confirm receipt or action taken. The filing asks investigators to examine possible 18 U.S.C. § 208 and Ethics in Government Act violations, but neither the submission nor the absence of a public OIG response establishes that Jackson violated either law or that a case was opened.

The clearest accountability question is narrower than the complaint’s legal theories. Jackson electronically signed a new-entrant financial report on October 17, 2025 and amended it through June 28, 2026. The report attached to the complaint listed her ownership and options in Evernow, the menopause-care company she founded, while the agency-ethics and Office of Government Ethics review-and-certification fields remained blank. A separate draft waiver described financial ties that otherwise required recusal from a significant portion of her ARPA-H duties, while saying HHS Ethics had advised her on those obligations and permitted broad Make America Healthy Again policy work. The public record does not show whether the waiver became final or what event-specific advice covered the November 10 appearance.

At the event, Jackson publicly praised the hormone-therapy policy change. Because the policy concerned the treatment market served by her former company, HHS has a public-interest obligation to explain and release any nonexempt clearance record—or say none exists. The strongest supported criticism is institutional: HHS featured Jackson as an official endorser in the rollout while the available record leaves event-specific clearance, final-waiver status and agency certification unresolved.

Important evidence cuts against a broader claim. FDA—not Jackson or ARPA-H—made the labeling decision. FDA convened an expert panel on July 17, 2025 and later gathered public comment before Jackson was sworn in on October 20. The complaint itself says it cannot directly link Jackson to FDA’s decision. FDA’s detailed November 10 labeling request removed specified cardiovascular-disease, breast-cancer and dementia statements from boxed warnings, retained the endometrial-cancer boxed warning for systemic estrogen-alone products and retained cardiovascular and breast-cancer risk information elsewhere in labeling.

HHS told ProPublica before the complaint that Jackson was on administrative leave and that it would assess the facts, without identifying the reason; leave is not a finding. Evernow told ProPublica that Jackson has no current financial interest in the company. The public record reviewed here does not establish when or on what terms any divestiture occurred, and the complaint’s characterization of the value of her interest does not align cleanly with the attached amended disclosure. Public Rot therefore is not publishing a dollar figure for that holding.

The complaint also alleges deficiencies in disclosure of interests tied to Jackson’s husband, including investment-fund holdings. Those claims require the underlying holdings, filing instructions and agency review—not an inference from a complaint alone. No public evidence reviewed here shows that Jackson steered an ARPA-H award or FDA action to a disclosed interest.

HHS should publish Jackson’s executed ethics agreement, any final waiver, the event-specific clearance or recusal advice for the November 10 appearance, and the dates and terms of any Evernow divestiture. HHS should also explain what internal review it began when it placed Jackson on leave and publish any completed findings that law and personnel rules permit. Until those records are public, accurate statements about FDA’s process cannot answer the separate question of whether HHS properly cleared its own official to promote the result.